• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A phase II study of ifosfamide in paediatric solid tumours.

作者信息

Pinkerton C R, Pritchard J

机构信息

Department of Haematology, Hospital for Sick Children, London, U.K.

出版信息

Cancer Chemother Pharmacol. 1989;24 Suppl 1:S13-5. doi: 10.1007/BF00253231.

DOI:10.1007/BF00253231
PMID:2758566
Abstract

A total of 20 children with recurrent or unresponsive tumours (10 Wilms' tumours, 3 rhabdomyosarcomas, 4 Ewing's sarcomas, 1 osteosarcoma, 1 hepatoblastoma, 1 hepatoma) were given ifosfamide as a 24-h infusion (5 g/m2), with mesna as a uroprotector. The number of courses ranged from 1 to 13 (median, 3), and the interval between them was 2-3 weeks. In all, 16 of these patients had previously received cyclophosphamide. Complete clinical responses (CRs) were seen in 3 cases (2 Wilms' tumours and 1 Ewing's sarcoma) and lasted 5, 7, and 9 months. Partial responses (PRs) were seen in 3 instances; mixed response or stable disease, in 4; and progressive disease, in 10. Treatment was well tolerated in most patients, with no cystitis or severe myelosuppression, but two children developed transient neurological symptoms and one became hypertensive. Nausea and vomiting were controlled by high-dose dexamethasone in most children.

摘要

相似文献

1
A phase II study of ifosfamide in paediatric solid tumours.
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S13-5. doi: 10.1007/BF00253231.
2
A phase II study of ifosfamide in children with recurrent solid tumours.
Cancer Chemother Pharmacol. 1985;15(3):258-62. doi: 10.1007/BF00263897.
3
Phase II study of ifosfamide as a single drug for relapsed paediatric patients.
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S11-2. doi: 10.1007/BF00253230.
4
Ifosfamide in pediatric malignant solid tumors.
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S24-7. doi: 10.1007/BF00253234.
5
A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S31-3. doi: 10.1007/BF00253237.
6
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.异环磷酰胺治疗青少年复发性肉瘤的II期研究。
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S25-8. doi: 10.1007/BF00647446.
7
Phase II trial of ifosfamide in children with malignant solid tumors.异环磷酰胺治疗儿童恶性实体瘤的II期试验。
Cancer Treat Rep. 1987 Feb;71(2):131-5.
8
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Semin Oncol. 1989 Feb;16(1 Suppl 3):51-5.
9
High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.高剂量异环磷酰胺联合美司钠进行尿路保护治疗尤因肉瘤。
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S40-4. doi: 10.1007/BF00253239.
10
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.环磷酰胺联合拓扑替康治疗复发或难治性实体瘤儿童:一项儿科肿瘤学组II期研究。
J Clin Oncol. 2001 Aug 1;19(15):3463-9. doi: 10.1200/JCO.2001.19.15.3463.

引用本文的文献

1
Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.异环磷酰胺、环磷酰胺及其代谢产物对培养的肾小管细胞的毒性作用。
Pediatr Nephrol. 1994 Apr;8(2):157-63. doi: 10.1007/BF00865466.
2
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.异环磷酰胺/美司钠。关于其抗肿瘤活性、药代动力学特性及在癌症治疗中疗效的综述。
Drugs. 1991 Sep;42(3):428-67. doi: 10.2165/00003495-199142030-00006.

本文引用的文献

1
The oxazaphosphorines.
Cancer Treat Rev. 1983 Sep;10 Suppl A:3-15. doi: 10.1016/s0305-7372(83)80002-4.
2
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.使用异环磷酰胺输注联合美司钠进行大剂量烷基化疗法治疗成人晚期软组织肉瘤。
Cancer Chemother Pharmacol. 1983;11(2):69-72. doi: 10.1007/BF00254247.
3
Ifosfamide--current aspects and perspectives.异环磷酰胺——当前状况与展望
Cancer Treat Rev. 1983 Sep;10 Suppl A:183-92. doi: 10.1016/s0305-7372(83)80027-9.
4
Clinical overview of mesna.美司钠的临床概述
Cancer Treat Rev. 1983 Sep;10 Suppl A:175-81. doi: 10.1016/s0305-7372(83)80026-7.
5
Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.单剂量异环磷酰胺:非小细胞肺癌的疗效研究。
Semin Oncol. 1982 Dec;9(4 Suppl 1):56-60.
6
A phase II study of ifosfamide in children with recurrent solid tumours.
Cancer Chemother Pharmacol. 1985;15(3):258-62. doi: 10.1007/BF00263897.
7
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.环磷酰胺与异环磷酰胺对比:成人软组织肉瘤随机II期试验的初步报告
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S13-6. doi: 10.1007/BF00647440.
8
Studies on the human pharmacokinetics of isophosphamide (NSC-109724).异环磷酰胺(NSC-109724)的人体药代动力学研究。
Cancer Treat Rep. 1976 Apr;60(4):451-8.
9
Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study.肾母细胞瘤的组织病理学与预后:来自首次全国肾母细胞瘤研究的结果。
Cancer. 1978 May;41(5):1937-48. doi: 10.1002/1097-0142(197805)41:5<1937::aid-cncr2820410538>3.0.co;2-u.